Researchers grow micro-tumour models for more targeted cancer therapy

September 11, 2017, Agency for Science, Technology and Research (A*STAR), Singapore
Credit: A*STAR’s Genome Institute of Singapore

Researchers have successfully grown micro-tumour models outside the human body and used them to identify alternative treatment options for cancer patients who are suffering from resistant and/or metastatic disease, meaning that they fail to respond to standard-of-care cancer drugs.

This approach shows the potential to predict response to drugs and help clinicians identify appropriate therapeutic options for . The study, published in Nature Communications, was jointly led by A*STAR's Genome Institute of Singapore (GIS) and National Cancer Centre Singapore (NCCS).

The study involved growing the ' own tumour material ex vivo in a dish as "micro-tumour avatars", with the team successfully generating 24 patient-derived "avatar-models". These micro-tumour models were then screened for therapeutic and genetic vulnerabilities against a panel of clinically relevant drugs, including standard-of-care treatments such as chemotherapy, radiotherapy or targeted anti-cancer drugs. This approach is known as phenotype-based treatment.

In addition, genomic characterisation of these models helped identify new biomarkers that could predict tumour progression as well as the patients' response to different classes of drugs.

Among the group of patients involved in the study, two of them went on to receive the phenotype-based treatment in the clinic, and responded remarkably well to the that were identified, including one where the tumour volume shrank by more than 95% within six weeks of treatment, and the other where the expression of a cancer antigen marker in the blood was reduced by over 90%.

The researchers plan to subsequently scale this effort to reveal specific predictive gene expression and mutation signatures that could be used to stratify different patient groups and corresponding treatment options. This would help to guide future treatment strategies validated through larger clinical trials.

"Our approach is unique in the sense that we are using phenotype-driven approaches prospectively to define real-time clinical management of disease, and then investigating the genomic basis for response to identify novel prognostic biomarkers. The ultimate goal would be for this innovative strategy to be available to every cancer patient in future," explained the study's lead author Dr Ramanuj DasGupta, Group Leader, Cancer Therapeutics and Stratified Oncology at the GIS.

Dr DasGupta added, "To truly assess what treatments may or may not work for a given patient, we need to let the patient's own cancer cells tell us the genetic basis for their response or lack thereof to certain treatments, instead of using historically existing cell lines. This approach would be exceptionally useful where there is a lack of treatment options, for instance in late-stage patients, or a lack of clear biomarker-driven treatment strategies."

"To get this right takes a lot more than just the work reflected in this paper alone. There were years of struggles on both sides to get protocols in place to be able to recruit patients, grow the tumours outside of the patient's body, testing for genetic and therapeutic vulnerabilities at the screening setup at GIS1, and have it run like clockwork, with data analysis in a meaningful manner, making sense of the results, bringing that information back to the hospital for discussions, and finally treating the patient again. Each of these steps is herculean to say the least but this is a small step towards the future where treatment for any patient will be based on their unique characteristics and not assumptions from group studies based on other populations. This takes planning, determination, mutual respect for each other's strength and a dedication to see this through," said Dr Gopal Iyer, co-lead author of the study and Senior Consultant Surgical Oncologist at the NCCS.

Executive Director of GIS, Prof Ng Huck Hui said, "Tumour heterogeneity poses a major challenge in cancer therapies because different clonal populations of cells within a tumour can respond very differently to standard-of-care treatments, often resulting in treatment failure or relapse for unknown reasons. I am delighted this multi-institutional collaborative effort has resulted in a novel approach that can help us advance precision medicine."

Cancer remains a major cause for disease-related mortality worldwide. It accounted for 8.8 million deaths in 2015; nearly 1 in 6 global deaths was due to cancer2. 70% of all deaths afflict people in the developing world, including countries in Africa, Asia, Central and South America.

Personalised screening for drug sensitivity in patient-derived models. Green cells represent the primary tumour cells while the red cells represent metastatic tumours. The different micrographs represent the effect of drug treatment on primary versus metastatic tumour models derived from the same patient.

The research findings described in this media release can be found in the scientific journal Nature Communications, under the title, "Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time."

Explore further: New study reveals late spread of breast cancer and backs key role of early diagnosis

More information: Shumei Chia et al. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time, Nature Communications (2017). DOI: 10.1038/s41467-017-00451-5

Related Stories

New study reveals late spread of breast cancer and backs key role of early diagnosis

August 14, 2017
Breast cancer cells that spread to other parts of the body break off and leave the primary tumour at late stages of disease development, scientists from the Wellcome Trust Sanger Institute and their collaborators have found.

DNA sequencing could open up new drug indications for patients with rare cancers

September 8, 2017
Thanks to DNA sequencing, patients with rare cancers for which no standard treatment is available could receive existing therapies that work in patients treated for different cancers, but who carry the same genetic mutations. ...

Characterising the profile of breast cancer metastases for improved treatment

April 24, 2017
Researchers at the Jules Bordet Institute - Université libre de Bruxelles, VIB and KU Leuven published this 21 of April an important study offering a better understanding of the progression of breast cancer. The conclusions ...

Research looks to slow prostate cancer's 'joyride'

July 25, 2017
When it comes to arresting cancer's joyride through the body, one Western researcher's work looks to be the 'traffic cop' on the bloodstream highway.

Researchers make breakthrough discovery in fight against bowel cancer

May 31, 2017
New research led by Queen's University Belfast has discovered how a genomic approach to understanding bowel (colorectal) cancer could improve the prognosis and quality of life for patients.

Blood test could predict best treatment for lung cancer

November 21, 2016
A blood test could predict how well small-cell lung cancer (SCLC) patients will respond to treatment, according to new research published in Nature Medicine today (Monday).

Recommended for you

Breast cancer researcher warns against online genetic tests

June 18, 2018
We have never been so fascinated by the secrets inside our cells.

Genomics offers new treatment options for infants with range of soft tissue tumors

June 18, 2018
The genetic causes of a group of related infant cancers have been discovered by scientists at the Wellcome Sanger Institute, the University of Wuerzburg and their collaborators. Whole genome sequencing of tumours revealed ...

Non-coding DNA reveals a route by which advanced prostate cancer resists treatment

June 15, 2018
Two research teams converge on epigenetic switches that feed treatment-resistant metastatic prostate tumors. This research highlights the value of exploring gene regulation and large-scale structural changes in the cancer ...

Researchers peer inside cells to spy on cancer's on-off switch

June 15, 2018
Forty years after researchers first discovered it in fruit flies, a once-obscure cluster of proteins called PRC2 has become a key target for new cancer-fighting drugs, due to its tendency—when mutated—to bind to and silence ...

PIM-2 protein kinase regulates T-cell activity differently than PIM-1 or PIM-3 isoform

June 15, 2018
The PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity, while PIM-1 and PIM-3 are positive regulators, report Medical University of South Carolina (MUSC) investigators in an article ...

Gene testing could identify men with prostate cancer who may benefit from immunotherapy

June 14, 2018
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.